On this page
What is Hepatitis?
Hepatitis is an inflammation of liver tissue. The word derives from the Greek hepar (liver) and -itis (inflammation). It is one of the most common liver conditions worldwide, with causes ranging from viral infections to alcohol, medications, and autoimmune processes.
Classification by Duration
Hepatitis is classified based on how long it lasts:
- Acute hepatitis: Lasts less than 6 months. It sometimes resolves on its own, but in other cases it can progress to chronic hepatitis or, rarely, directly to fulminant hepatitis.
- Chronic hepatitis: Lasts more than 6 months. Over time, it can progress to:
- Liver cirrhosis, a chronic degenerative disorder
- Liver failure (hepatic insufficiency): a severe reduction in liver function.
- Hepatocellular carcinoma (liver cancer), a primary malignancy of the liver
Main Causes
Causes of hepatitis are broadly divided into infectious and non-infectious:
Infectious (viral) hepatitis is the most common type worldwide. There are five main types:
- Hepatitis A
- Hepatitis B
- Hepatitis C
- Hepatitis D
- Hepatitis E
Non-infectious hepatitis includes:
- Alcoholic hepatitis
- Drug-induced and toxic hepatitis
- Autoimmune hepatitis
- Non-alcoholic steatohepatitis (NASH)
Key Symptoms at a Glance
Acute hepatitis may sometimes be entirely asymptomatic, while in other cases it presents with characteristic signs:
- Jaundice: yellowing of the skin and whites of the eyes, also known as the sclera
- Light-colored stools
- Dark-colored urine
- Enlarged liver (hepatomegaly), palpable and sometimes tender
Chronic hepatitis, particularly when it has evolved into cirrhosis, presents with signs of long-standing liver dysfunction:
- Easy bruising and bleeding
- Ascites (fluid accumulation in the abdomen)
- Edema of the lower limbs (swollen legs and ankles)
Causes
Infectious Hepatitis
Viral Hepatitis: The Most Common Form Worldwide
Viral hepatitis can be caused by five distinct viruses (A, B, C, D, and E), each with different transmission routes, clinical behavior, and long-term outcomes.
Hepatitis A and Hepatitis E are both transmitted via the fecal-oral route, primarily through ingestion of food or water contaminated with infected human feces. They are more prevalent in developing countries with inadequate sanitation infrastructure. Both are typically self-limiting diseases that do not progress to chronic hepatitis.
- Hepatitis A remains common in areas with inadequate sanitation and can also occur in developed countries, often linked to consumption of raw or undercooked shellfish and mollusks.
- Hepatitis E is uncommon in many Western countries and is more typical of South and Southeast Asian nations such as India, though locally acquired cases through undercooked pork are increasingly recognized in Europe.
Hepatitis B, C, and D are transmitted primarily through blood and blood-derived products, including:
- Sharing needles or syringes (intravenous drug use)
- Unscreened blood transfusions (a significant issue in the past, now largely controlled)
- Direct contact of infected blood with open wounds or cuts
- Use of non-sterile instruments for tattoos, ear or nasal piercings, body piercing, and acupuncture
- Sexual transmission (most relevant for Hepatitis B)
- Mother-to-child transmission during childbirth or transplacentally during pregnancy
Important: Transmission through saliva has not been documented, unless saliva comes into direct contact with open wounds or cuts.
Hepatitis B in adults is most commonly self-limiting. However:
- Less than 5% of adult cases progress to chronic infection
- Chronic Hepatitis B progresses to cirrhosis in approximately 30% of cases, and to hepatocellular carcinoma in about 5%
- In contrast, newborns and young children infected with Hepatitis B frequently develop chronic infection, as their immune systems are not yet fully developed
Hepatitis C, unlike Hepatitis B, progresses to chronic infection in the majority of cases. Chronic Hepatitis C is one of the leading causes of cirrhosis worldwide. In the United States, it is the second most common cause of liver cirrhosis, surpassed only by alcoholic hepatitis.
Hepatitis D is a defective virus that requires the co-presence of Hepatitis B to replicate. It can only infect individuals who are already infected with HBV.
Other Infectious Causes of Hepatitis
While viral hepatitis A through E accounts for the vast majority of cases, other infectious agents can occasionally cause liver inflammation:
Bacteria:
- Escherichia coli
- Klebsiella pneumoniae
- Neisseria meningitidis
- Neisseria gonorrhoeae
- Bartonella henselae
- Borrelia burgdorferi
- Salmonella species
- Brucella species
- Campylobacter
- Mycobacteria
- Treponema pallidum
- Coxiella burnetii
- Rickettsia species
Other viruses:
- Cytomegalovirus (CMV)
- Epstein-Barr Virus (EBV)
- Varicella-Zoster Virus (VZV): chickenpox and herpes zoster
- Herpes Simplex Virus (HSV)
Parasites:
- Trypanosoma cruzi (Chagas disease)
- Leishmania species
- Plasmodium (Malaria)
- Entamoeba histolytica
- Echinococcus granulosus
Non-Infectious Hepatitis
Alcoholic Hepatitis
Alcoholic hepatitis is a very common form of hepatitis caused by excessive and prolonged alcohol consumption. When chronic, it is the most common cause of liver cirrhosis, which can in turn progress to hepatocellular carcinoma.
Hepatitis typically develops after years of heavy alcohol exposure, generally defined as:
- More than 30–40 grams of alcohol per day in men
- More than 20 grams per day in women
💡 For reference: a standard drink (one glass of wine, one beer, or one shot of spirits) contains approximately 10–14 grams of pure alcohol.
Drug-Induced and Toxic Hepatitis
Many chemical agents, including prescription medications, over-the-counter drugs, industrial toxins, and herbal preparations, can cause liver inflammation. The spectrum of drug-induced liver injury (DILI) ranges from mild acute hepatitis to fulminant liver failure.
Mechanisms of liver injury include:
- Direct cellular toxicity (dose-dependent)
- Metabolic disruption at the cellular level
- Idiosyncratic reactions: unpredictable, dose-independent immune-mediated responses that vary between individuals
Examples:
- Paracetamol: Dose-dependent hepatotoxicity; one of the leading causes of acute liver failure in the Western world when taken in overdose
- Isoniazid: Idiosyncratic reaction; dose-independent
- Nitrofurantoin: Can cause both acute and chronic hepatitis
- Amoxicillin-clavulanate (Augmentin): One of the most common causes of drug-induced liver injury
- Erythromycin
- Valproate
- Phenytoin
- Statins
- Oral contraceptives
- Anabolic steroids
Drug-induced hepatitis can also present with systemic signs of an allergic reaction, including skin rash, fever, serositis (inflammation of organ-lining membranes), elevated eosinophils (a type of white blood cell), and bone marrow suppression.
Non-Alcoholic Steatohepatitis (NASH)
Non-alcoholic steatohepatitis (NASH) is a form of liver inflammation that occurs in people with little or no history of alcohol use. It is strongly associated with cardiometabolic risk factors and lifestyle, particularly:
- Metabolic syndrome
- Obesity and overweight
- Insulin resistance
- Type 2 diabetes mellitus
- Hypertriglyceridemia
10 to 25% of patients with NASH develop cirrhosis. NASH is the third most common cause of liver disease in the United States and is projected to become a leading cause of liver transplantation in the coming decades.
Autoimmune Hepatitis
Autoimmune hepatitis is a chronic liver disease caused by an abnormal immune response directed against the body’s own liver cells (hepatocytes). It shows a certain genetic predisposition, with an association with HLA-DR3 and DR4 haplotypes and a significantly higher prevalence in women.
The aberrant immune response may be triggered by:
- Medications (e.g., nitrofurantoin, hydralazine, methyldopa)
- Liver transplantation
- Viral infections (Hepatitis A virus, Epstein-Barr virus, measles virus)
Without treatment, autoimmune hepatitis can progress to cirrhosis and liver failure.
Symptoms
Hepatitis presents across a wide clinical spectrum, from a complete absence of symptoms to severe liver failure. The clinical picture depends on the underlying cause, the acuity of onset, and the degree of liver damage.
Acute Hepatitis
Acute viral hepatitis follows a relatively predictable clinical course, divided into three phases:
Phase 1: Prodromal Phase
Duration: 3–4 days to 2–3 weeks (may be absent in some patients)
This phase is characterized by non-specific, flu-like symptoms:
- Fatigue and malaise
- Nausea and vomiting
- Poor appetite (anorexia)
- Joint pain (arthralgia)
- Headache
- Fever
Phase 2: Symptomatic (Icteric) Phase
Duration: Develops approximately 1–2 weeks after the prodromal phase; can last up to 4 weeks
This is the phase in which the most characteristic and clinically significant signs of hepatitis appear:
- Jaundice: yellowing of the skin and the sclera (whites of the eyes), caused by elevated bilirubin
- Light-colored (pale or clay-colored) stools: due to reduced bile flow into the intestine
- Dark urine: classically described as “Marsala wine” colored due to urinary excretion of conjugated bilirubin
- Enlarged liver (hepatomegaly): palpable on physical examination and sometimes tender
- Mild splenomegaly: slight enlargement of the spleen, which may be palpable in some patients
Phase 3: Recovery Phase
Characterized by the gradual resolution of signs and symptoms. In most cases, acute hepatitis resolves completely, both anatomically and functionally, within 20 to 45 days from the onset of jaundice.
However, convalescence is often prolonged. Residual symptoms that may persist for some time include:
- Difficulty with digestion
- Mild sub-icteric (slightly yellowish) discoloration of the sclera
- A sense of heaviness or discomfort in the right upper abdomen
- General malaise
Note on drug-induced hepatitis: In addition to the typical hepatitis symptoms, drug-induced hepatitis may also present with systemic signs of allergic reaction, including rash, fever, serositis, elevated eosinophils, and bone marrow suppression.
Chronic Hepatitis
Chronic hepatitis is defined as persistent liver inflammation lasting more than 6 months. It is often asymptomatic in its early stages and may only be detected incidentally through abnormal liver function tests during routine blood work or screening for unrelated conditions.
As inflammation progresses, patients may develop constitutional symptoms similar to those of acute hepatitis:
- Fatigue
- Nausea and vomiting
- Poor appetite
- Joint pain
Jaundice may or may not be present, but when it appears, it typically indicates significantly advanced disease.
Hormonal Manifestations
Because the liver plays a critical role in hormone metabolism, chronic hepatitis can interfere with hormonal function, manifesting as:
- Acne
- Hirsutism (abnormal hair growth)
- Amenorrhea (absence of menstruation)
Progression to Cirrhosis
Over time, chronic hepatitis can evolve into cirrhosis, a condition in which liver function is irreversibly compromised due to extensive scarring (fibrosis). Cirrhosis manifests with:
- Jaundice
- Unintentional weight loss
- Coagulopathy (impaired blood clotting), particularly easy bleeding and bruising
- Ascites (fluid accumulation in the abdominal cavity)
- Peripheral edema, particularly leg swelling
Cirrhosis itself can lead to potentially life-threatening complications, including:
- Hepatic encephalopathy: brain dysfunction due to the liver’s inability to filter toxins
- Esophageal varices: enlarged, fragile blood vessels at risk of rupture and severe hemorrhage
- Hepatorenal syndrome: progressive kidney failure secondary to liver failure
- Hepatocellular carcinoma (liver cancer)
Fulminant Hepatitis
Fulminant hepatitis is defined as the massive, rapid destruction of a large proportion of liver cells over a very short period of time. It represents one of the most critical medical emergencies in gastroenterology.
Who Is at Risk?
Fulminant hepatitis is a rare but life-threatening complication of acute hepatitis, occurring most commonly in the context of:
- Hepatitis B, D, and E infection
- Autoimmune hepatitis
- Drug-induced or toxic hepatitis
It occurs with greatest frequency in:
- HBV/HDV co-infection
- Pregnant women infected with Hepatitis E, particularly in the third trimester
Clinical Presentation
Fulminant hepatitis presents with all the classic symptoms of acute hepatitis, plus:
- Coagulopathy, particularly severe and uncontrolled bleeding
- Hepatic encephalopathy, manifesting as:
- Confusion and disorientation
- Progressive drowsiness
- Coma in the most severe cases
Prognosis and Treatment
The mortality rate of fulminant hepatitis is extremely high. Without intervention, the prognosis is grave. The only definitive treatment in many cases is urgent liver transplantation, which must be performed as quickly as possible before irreversible multiorgan failure develops.
Diagnosis
The diagnosis of hepatitis is based on a combination of clinical assessment, laboratory tests, and, in selected cases, imaging and liver biopsy.
1. Medical History (Anamnesis)
A thorough medical history is essential and should include:
- History of alcohol and substance use
- Sexual history and number of partners
- Medication use (including herbal supplements)
- Recent travel to endemic regions
- Occupational and environmental exposures
- Family history of liver disease
2. Physical Examination
Clinical assessment focuses on identifying signs of liver disease, including jaundice, hepatomegaly, splenomegaly, ascites, peripheral edema, and signs of coagulopathy (bruising, bleeding).
3. Laboratory Tests
Liver Enzymes
- Transaminases (AST and ALT): The cornerstone of hepatitis diagnosis; markedly elevated in acute hepatitis, indicating hepatocellular injury
- GGT (gamma-glutamyl transferase): Elevated in many forms of liver disease; particularly sensitive for alcohol-related liver damage
- Bilirubin: Elevated in cholestatic and hepatocellular disease; responsible for jaundice
- Alkaline phosphatase (ALP): Marker of biliary obstruction and liver infiltration
Serological and Molecular Tests
- Serology (antibody testing): Detection of virus-specific antibodies (e.g., IgM anti-HAV, HBsAg, IgM anti-HBc, anti-HCV, anti-HDV, IgM anti-HEV)
- PCR (polymerase chain reaction): Detection of viral DNA or RNA, confirming active replication (e.g., HBV DNA, HCV RNA, HEV RNA)
- Autoimmune markers: ANA, SMA, anti-LKM1 antibodies for autoimmune hepatitis
Coagulation Tests
- Prothrombin time (PT/INR): Assesses the liver’s synthetic function; prolonged in severe hepatitis and liver failure
4. Imaging Studies
- Abdominal ultrasound: First-line imaging; evaluates liver size, echogenicity, presence of ascites, biliary obstruction, and portal hypertension
- CT scan (computed tomography): Provides greater detail, particularly for characterizing liver lesions and detecting complications
- MRI (magnetic resonance imaging): Superior soft-tissue contrast; particularly useful for characterizing focal liver lesions and assessing fibrosis
📋 CT and MRI offer greater diagnostic detail than ultrasound but are more costly and are generally reserved for cases where initial testing is inconclusive or when complications are suspected.
5. Liver Biopsy
In most cases of viral hepatitis, blood tests and clinical presentation are sufficient for diagnosis. However, for non-infectious forms (especially autoimmune hepatitis and NASH), liver biopsy may be necessary to:
- Confirm the diagnosis
- Assess the degree of fibrosis and inflammation
- Guide treatment decisions
Note: Liver biopsy is an invasive procedure with a small but meaningful risk of bleeding, a risk that is further elevated in patients with coagulopathy secondary to liver damage. It is therefore typically not used as an initial diagnostic test, but rather when other methods are insufficient.
Treatment
Because hepatitis has multiple causes with fundamentally different pathophysiological mechanisms, treatment must always be individualized according to the underlying etiology. There is no one-size-fits-all approach.
The following summarizes the general principles of management for each major cause:
Viral Hepatitis
Acute viral hepatitis:
- Treatment is primarily symptomatic and supportive in most cases, as the majority of patients clear the infection spontaneously
- Rest, hydration, avoidance of alcohol, and avoidance of hepatotoxic medications
Chronic viral hepatitis (B, C, and D):
- Specific antiviral therapies are used:
- Hepatitis B: Pegylated interferon-alpha, nucleoside/nucleotide analogues such as Entecavir and Tenofovir suppress viral replication and reduce the risk of disease progression
- Hepatitis C: Direct-acting antivirals (DAAs) such as Sofosbuvir/Ledipasvir and Glecaprevir/Pibrentasvir are highly effective, achieving cure rates over 95% in most patients
- Hepatitis D: Pegylated interferon-alpha; Bulevirtide (conditionally approved in Europe). Response rates remain suboptimal
Alcoholic Hepatitis
- The only definitive treatment is complete and permanent abstinence from alcohol
- Adjunct therapies include:
- Nutritional support and dietary supplements (thiamine, folate, zinc)
- Pentoxifylline (reduces inflammation)
- Corticosteroids (e.g., prednisolone) for severe acute alcoholic hepatitis
- In cases where alcoholic hepatitis has led to advanced cirrhosis, liver transplantation may be the only viable option
Non-Alcoholic Steatohepatitis (NASH)
- The cornerstone of treatment is lifestyle modification: dietary changes to achieve sustained weight loss, increased physical activity
- Weight loss of 5–10% of body weight has been shown to significantly reduce liver inflammation and fibrosis
- Pharmacological approaches target underlying metabolic dysfunction:
- Metformin and glitazones (thiazolidinediones) to address insulin resistance
- Vitamin E: shown to reduce liver inflammation in non-diabetic NASH patients
- Emerging therapies targeting metabolic pathways are under active investigation in clinical trials
Autoimmune Hepatitis
- Treatment is based on immunosuppressive therapy to reduce the abnormal immune attack on liver cells:
- Corticosteroids (e.g., prednisone or budesonide), typically used as first-line induction therapy
- Azathioprine is often used in combination with corticosteroids for long-term maintenance to reduce steroid side effects
- Treatment is generally required long-term, and relapse upon withdrawal of therapy is common
- In cases of treatment failure or progression to end-stage liver disease, liver transplantation may be considered
💡 Bottom line for patients: If you experience symptoms suggestive of hepatitis, particularly jaundice, persistent fatigue, dark urine, or abdominal discomfort, seek medical evaluation promptly. Early diagnosis and appropriate management are essential to prevent progression to serious complications such as cirrhosis and liver cancer.
Sources and Bibliography
- World Health Organization (WHO). Hepatitis Fact Sheets
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) – NIH. Viral Hepatitis
- Hoofnagle JH, Björnsson ES. “Drug-Induced Liver Injury: Types and Phenotypes”. N Engl J Med. 2019;381(3):264–273. doi:10.1056/NEJMra1816149
- Mak LY, Cruz-Ramón V, Chinchilla-López P, et al. “Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma”. Am Soc Clin Oncol Educ Book. 2018;38:262–279.
- European Association for the Study of the Liver (EASL). “EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection”. J Hepatol. 2017;67(2):370–398. doi:10.1016/j.jhep.2017.03.021
- EASL. “Recommendations on Treatment of Hepatitis C 2018”. J Hepatol. 2018;69(2):461–511.
- Manns MP, Lohse AW, Vergani D. “Autoimmune Hepatitis: Update 2015”. J Hepatol. 2015;62(1 Suppl):S100–S111.
- Chalasani N, Younossi Z, Lavine JE, et al. “The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases”. Hepatology. 2018;67(1):328–357.
- Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH. “ACG Clinical Guideline: Alcoholic Liver Disease”. Am J Gastroenterol. 2018;113(2):175–194.
